STAT3, an oncogenic protein, has been targeted with a novel formulation of nanoparticles packaged with STAT 3 inhibitor linked with anti-CD38 mAb that improved uptake by MM cell lines; these nanoparticles depicted a 4-fold reduction in tumor size compared with nanoparticles carrying STAT3 inhibitor only [59]. Here, CD38 is linked to Miyoshi myopathy.